Filing Flows

Filing Flows › Companies › Actinium Pharmaceuticals › Cash flow

Actinium Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$5.7M in Q2 2026 · −$22.7M over twelve months

Operating cash flow−$5.2M
Capital spending−$478K
Free cash flow−$5.7M
Cash / net income-0.2×

Analysis

In Q2 2026, Actinium Pharmaceuticals generated −$5.2M of operating cash flow and spent $478K on capital projects, leaving free cash flow of −$5.7M. That is $265K less than in Q2 2025 (−$5.4M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$22.7M; the largest uses were operating cash flow ($22.7M), other financing ($207K), net borrowing (+) / repaid (−) ($10K); the cash balance fell by $23.4M.

Operating cash flow was −$5.2M against net income of $27.9M — -0.2× profit, less cash than reported earnings, worth checking against working capital. The largest differences: payables +$1.9M, depreciation & amortization +$432K, prepaid and other assets −$138K.

Free cash flow

Actinium Pharmaceuticals: free cash flow by quarterActinium Pharmaceuticals: free cash flow by quarter−$12.0MQ3 2024−$5.8MQ4 2024−$7.6MQ1 2025−$5.4MQ2 2025−$6.3MQ3 2025−$5.3MQ4 2025−$5.9MQ1 2026−$5.7MQ2 2026
Operating cash flow less capital spending.
Actinium Pharmaceuticals: operating cash flow against capital spendingActinium Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$12.0M$0Q3 2024−$5.8M$0Q4 2024−$7.6M$0Q1 2025−$5.4M$0Q2 2025−$6.3M$0Q3 2025−$5.3M$0Q4 2025−$5.9M$2KQ1 2026−$5.2M$478KQ2 2026
Latest (Q2 2026): Operating cash flow −$5.2M, Capital spending $478K.

Capital allocation, year by year

Actinium Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearActinium Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$20.9MFY2021: Net borrowing −$85KFY2021: Shares issued $35.3MFY2021: Capital spending −$133K$35.3MFY2021FY2022: Operating cash flow $8.6MFY2022: Net borrowing $751KFY2022: Shares issued $23.2MFY2022: Capital spending −$366K$32.6MFY2022FY2023: Operating cash flow −$47.3MFY2023: Net borrowing −$4KFY2023: Shares issued $14.9MFY2023: Capital spending −$153K$14.9MFY2023FY2024: Operating cash flow −$33.1MFY2024: Net borrowing −$9KFY2024: Shares issued $29.3MFY2024: Capital spending −$11K$29.3MFY2024FY2025: Operating cash flow −$24.6MFY2025: Net borrowing −$10KFY2025: Capital spending −$104KFY2025
Over these 5 years operating cash flow totalled −$117M; the largest uses were operating cash flow ($126M) and capital spending ($767K). Cash-flow statements as filed.

Where the cash came from and went

Actinium Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Actinium Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$5.7MOperating cash flow−$5.2MCapital spending−$478KNet borrowing (+) / repaid (−)−$2KExchange rates$2K
Actinium Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Actinium Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Cash drawn (+) / kept (−)$23.4MOperating cash flow−$22.7MNot reconciled−$565KOther financing−$207KNet borrowing (+) / repaid (−)−$10K

From profit to cash

Actinium Pharmaceuticals: net income to operating cash flow, Q2 2026Actinium Pharmaceuticals: net income to operating cash flow, Q2 2026Net income$27.9MDepreciation & amortization$432KStock-based pay$118KPayables$1.9MPrepaid and other assets−$138KOperating cash flow−$5.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$5.2M−$478K−$2K—$5.7M−$5.7M
Q1 2026−$5.9M−$2K−$3K—$5.9M−$5.9M
Q4 2025−$5.3M—−$3K—$5.3M−$5.3M
Q3 2025−$6.3M—−$2K—$6.5M−$6.3M
Q2 2025−$5.4M—−$3K—$5.4M−$5.4M
Q1 2025−$7.6M—−$2K—$7.6M−$7.6M
Q4 2024−$5.8M—−$2K−$1K$5.8M−$5.8M
Q3 2024−$12.0M—−$2K$4.6M$7.4M−$12.0M

Actinium Pharmaceuticals: income statement and cash flow

Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%. The chart follows the revenue to costs, profit and cash.

Actinium Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.